The DOI matches its Crossref record; 257 of the 257 references it cites were found in a registry or an index.
Non-small-cell lung cancer
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024) · CA: a cancer journal for clinicians · doi:10.3322/caac.21834 · Cited by 27,064
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
The National Lung Screening Trial Research Team (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102873 · Cited by 11,064
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Self-citationHallmarks of Cancer: New Dimensions
Hanahan, D. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1059 · Cited by 9,887
Research works printed but not linked: 28
- World Health Organization. WHO Global Report on Trends in Prevalence of Tobacco Use 2000–2025, fourth edition (WHO, 2021).
- Akhtar-Danseh, G. G., Akhtar-Danesh, N. & Finley, C. Uptake and survival effects of minimally invasive surgery for lung cancer: a population-based study. Eur. J. Surg. Oncol. 47, 1791–1796 (2021). · doi:10.1016/j.ejso.2021.01.002
- WHO Classification of Tumours Editorial Board. Thoracic Tumours, WHO Classification of Tumours 5th edn, Vol. 5 (WHO, 2021).
- Kerr, K. M. in Molecular Pathology of Lung Cancer (eds. Cagle, P. T. et al.) 35–52 (Springer, 2012). A key overview of the molecular classification of lung cancer. · doi:10.1007/978-1-4614-3197-8_5
- Minna, J. D., Fong, K., Zöchbauer-Müller, S. & Gazdar, A. F. Molecular pathogenesis of lung cancer and potential translational applications. Cancer J. 8, S41–S46 (2002).
- Amin, M. et al. AJCC Cancer Staging Manual 8th edn (Springer, 2017).
- Hendriks, L. E. et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann. Oncol. 34, 339–357 (2023). European Society for Medical Oncology recommendations on the management of oncogene-addicted NSCLC. · DOI · Paper page
- Poon, C., Wilsdon, T., Sarwar, I., Roediger, A. & Yuan, M. Why is the screening rate in lung cancer still low? A seven-country analysis of the factors affecting adoption. Front. Public Health 11, 1264342 (2023). · doi:10.3389/fpubh.2023.1264342
- Hanash, S. M., Ostrin, E. J. & Fahrmann, J. F. Blood based biomarkers beyond genomics for lung cancer screening. Transl. Lung Cancer Res. 7, 327–335 (2018). · doi:10.21037/tlcr.2018.05.13
- Heiden, B. T. et al. Association between surgical quality metric adherence and overall survival among US veterans with early-stage non-small cell lung cancer. JAMA Surg. 158, 293–301 (2023). · doi:10.1001/jamasurg.2022.6826
- Whitson, B. A., D’Cunha, J. & Maddaus, M. A. Minimally invasive cancer surgery improves patient survival rates through less perioperative immunosuppression. Med. Hypotheses 68, 1328–1332 (2007). · doi:10.1016/j.mehy.2006.09.063
- Veronesi, G. et al. Robotic resection of Stage III lung cancer: an international retrospective study. Eur. J. Cardiothorac. Surg. 54, 912–919 (2018). · doi:10.1093/ejcts/ezy166
- Savonitto, E., Yasufuku, K. & Wallace, A. M. Robotic segmentectomy for early-stage lung cancer. Front. Surg. 10, 1090080 (2023). · doi:10.3389/fsurg.2023.1090080
- Veronesi, G. et al. Perioperative outcome of robotic approach versus manual videothoracoscopic major resection in patients affected by early lung cancer: results of a randomized multicentric study (ROMAN study). Front. Oncol. 11, 726408 (2021). · doi:10.3389/fonc.2021.726408
- Patel, Y. S. et al. RAVAL trial: protocol of an international, multi-centered, blinded, randomized controlled trial comparing robotic-assisted versus video-assisted lobectomy for early-stage lung cancer. PLoS ONE 17, e0261767 (2022). · doi:10.1371/journal.pone.0261767
- Houda, I. et al. OA06.03. An international EORTC survey on resectability of stage III non-small cell lung cancer. J. Thorac. Oncol. 18, S55–S56 (2023). · doi:10.1016/j.jtho.2023.09.044
- Dingemans, A. M. et al. OA06.05. Consensual definition of stage III NSCLC resectability: EORTC-lung cancer group initiative with other scientific societies. J. Thorac. Oncol. 18, S57–S58 (2023). · doi:10.1016/j.jtho.2023.09.046
- Perez, C. A. et al. A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the Radiation Therapy Oncology Group. Cancer 45, 2744–2753 (1980). · doi:10.1002/1097-0142(19800601)45:11<2744::aid-cncr2820451108>3.0.co;2-u
- Filippi, A. R. R. et al. LBA62. Durvalumab after radiotherapy (RT) in patients with unresectable stage III NSCLC ineligible for chemotherapy (CT): primary results from the DUART study. Ann. Oncol. 34, S1302 (2023). · doi:10.1016/j.annonc.2023.10.058
- Ko, R. et al. 1292MO. A phase II study of daily carboplatin plus irradiation followed by durvalumab for unresectable III non-small cell lung cancer patients with PS 2 or elderly (≧75 years): NEJ039A. Ann. Oncol. 34, S745–S746 (2023). · doi:10.1016/j.annonc.2023.09.770
- Hendriks, L. E. et al. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 34, 358–376 (2023). · DOI · Paper page
- Genentech. Genentech reports interim results for phase III SKYSCRAPER-01 study in PD-L1-high metastatic non-small cell lung cancer. gene.com https://www.gene.com/media/press-releases/14951/2022-05-10/genentech-reports-interim-results-for-ph (2022).
- Neal, J. et al. 60 CONTACT-01: Efficacy and safety from a phase III study of atezolizumab (atezo) + cabozantinib (cabo) vs docetaxel (doc) monotherapy in patients (pts) with metastatic NSCLC (mNSCLC) previously treated with checkpoint inhibitors and chemotherapy. J. Thorac. Oncol. 18, S39–S40 (2023). · doi:10.1016/s1556-0864(23)00260-5
- Paz-Ares, L. et al. 1194MO Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3 L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III results. Ann. Oncol. 32, S953–S954 (2021). · doi:10.1016/j.annonc.2021.08.1799
- Ahn, M. J. et al. LBA12 Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): results of the randomized phase III study TROPION-Lung01. Ann. Oncol. 34, S1305–S1306 (2023). · doi:10.1016/j.annonc.2023.10.061
- Sanofi announces end of program evaluating tusamitamab ravtansine after a 2 L NSCLC phase 3 trial did not meet a primary endpoint. Sanofi https://www.sanofi.com/en/media-room/press-releases/2023/2023-12-21-06-30-00-2799759 (2023).
- Camidge, D. R. et al. Telisotuzumab vedotin monotherapy in patients with previously treated c-Met–overexpressing non-squamous EGFR wildtype advanced NSCLC: primary analysis of the LUMINOSITY trial. J. Clin. Oncol. 42, 103–103 (2024). · doi:10.1200/jco.2024.42.16_suppl.103
- Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer. Cochrane Database Syst. Rev. 5, CD007309 (2010). A Cochrane Review providing confirmation of the efficacy of chemotherapy in advanced NSCLC.
Cited by
Zheng, Q., Liu, Y., Li, T., Zhang, X., Geng, Y., Chen, Z., Zhou, J., Fan, W., Wang, Y., Zhang, L., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1871582
Metadata
- Authors
- Hendriks, L. E. L., Remon, J., Faivre-Finn, C., Garassino, M. C., Heymach, J. V., Kerr, K. M., Tan, D. S. W., Veronesi, G., & Reck, M.
- Venue
- Nature Reviews Disease Primers
- Published
- 2024-09-26
- Volume
- 10
- Issue
- 1
- Pages
- 71-71
- ISSN
- 2056-676X (ISSN-L)
- OpenAlex
- W4402886999
- Cited by
- 568
- References
- 257
- FWCI
- 68.13
- Type
- journal article
- Language
- en
- Update notices
- correction (2025-01-07)
- Open access
- green
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Non-small-cell lung cancer. https://app.cochat.ai/papers/10.1038/s41572-024-00551-9
- The paper
- Hendriks, L. E. L., Remon, J., Faivre-Finn, C., Garassino, M. C., Heymach, J. V., Kerr, K. M., Tan, D. S. W., Veronesi, G., & Reck, M. (2024). Non-small-cell lung cancer. Nature Reviews Disease Primers. https://doi.org/10.1038/s41572-024-00551-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.